Mucosal immunity and vaccination against HIV

AIDS

Volumn 16, Issue SUPPL. 4, 2002, Pages

  Lehner, Thomas ^a   Anton, Peter A ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adaptive; HIV SIV; Immunization; Innate; Mucosal

Indexed keywords

ADJUVANT; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN ANTIBODY; RECEPTOR;

ADAPTATION; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNIZATION; INTESTINE CELL; LANGERHANS CELL; MOUTH MUCOSA; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REVIEW; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SQUAMOUS EPITHELIUM; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VAGINA MUCOSA; VIRUS INFECTION; VIRUS STRAIN;

AIDS VACCINES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; MALE; RECTUM; VAGINA;

EID: 0037004643     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200216004-00017     Document Type: Review

References (104)

1. Weiner HL. Oral tolerance immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997, 18:335-343.
2. Mowat AM, Vinney JL. The anatomical basis of intestinal immunity. Immunol Rev 1997, 156:145-166.
3. Lehner T, Bergmeier L, Wang Y, Mitchell E. A rational basis for mucosal vaccination against HIV infection. Immunol Rev 1999, 170:183-196.
4. Mitchell EA, Bergmeier LA, Doyle C, et al. Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Eur J Immunol 1998, 28:3066-3074.
5. McDermott MR, Bienenstock J. Evidence for a common mucosal system. I. Migration of B immunoblasts into intestinal, respiratory and genital tissues. J Immunol 1979, 122:1892.
6. Lehner T, Bergmeier LA, Panagiotidi C, et al. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 1992, 258:1365-1369.
7. Lehner T, Brookes R, Panagiotidi C, et al. T and B cell functions and epitope expression in non-human primates immunized with SIV by the rectal as compared with the systemic route. Proc Natl Acad Sci USA 1993, 90:8638-8642.
8. Belyakov IM, Derby MA, Ahlers JD, et al. Mucosal immunisation with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccine challenge. Proc Natl Acad Sci USA 1998, 95:1709-1714.
9. Eriksson K, Quiding-Jarbrink M, Osek J, et al. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun 1999, 66:5889-5896.
10. Bourinbaiar AS, Phillips DM. Transmission of human immunodeficiency virus from monocytes to epithelia. J Acquir Immune Defic Syndr 1991, 4:56-63.
11. Yahi N, Baghdiguian S, Moreau H, Fantini J. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J Virol 1992, 66:4848-4854.
12. Furuta Y, Eriksson K, Svennerholm B, et al. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc Natl Acad Sci USA 1994, 91:12559-12563.
13. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell barrier. Nature Med 1997, 3:42-47.
14. + cells. Nature Med 2002, 8:150-156.
15. Dalgleish AG, Beverley PC, Clapham PR, et al. The CD4 (T4] antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
16. Granelli-Piperno A, Pope M, Inaba K, Steinman RM. Co-expression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced dendritic cell-T-cell synctia. Proc Natl Acad Sci USA 1995, 92:10944-10948.
17. Hussain LA, Lehner T. Comparative investigation of Langerhans cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunol 1995, 85:475-484.
18. Geijtenbeek TBH, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T cells. Cell. 2000, 100:587-597.
19. Geijtenbeek TBH, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
20. Owen RL, Nemanic P. Antigen processing structures of the mammalian intestinal tract: an SEM study of lymphoepithelial organs. Scanning Electron Microsc 1978, 2:367-378.
21. O'Leary AD, Sweeney EC. Lymphoglandular complexes of the colon: structure and distribution. Histopathology 1986, 10:267-283.
22. Amerongen HM, Weltzin R, Farnet CM, et al. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J Acquir Immune Defic Syndr 1991, 4:760-765.
23. Lehner T. Innate Immunity in HIV. In AIDS Vaccine Research. Edited by Wong-Staal and Gallo RC. USA: Marcel Dekker Inc; 2002: 261-286.
24. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000, 290:84-89.
25. Moretta A, Biassoni R, Bottino C, et al. Natural cytotoxicity receptors that trigger human NK-cell mediated cytolysis. Immunol Today 2000, 21:228-234.
26. Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Ann Rev Immunol 1999, 17:189-200.
27. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today 2000, 21:447-455.
28. Wallace M, Bartz SR, Chang W-L, et al. γδ T lymphocyte responses to human immuno-deficiency virus. Clin Exp Immunol 1996, 103:177-184.
29. Lehner T, Mitchell E, Bergmeier L, et al. The role of γδ T cells in generating antiviral factors and β-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 2000, 30:2245-2256.
30. Hinz T, Wesch D, Friese K, et al. T cell γδ repertoire in HIV-1 infected individuals. Eur J Immunol 1994, 24:3044-3049.
31. + T cell expansion in the peripheral blood of HIV-infected persons. J Immunol 1995, 154:1418-1431.
32. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563-1566.
33. + T cells. Immunol Today 1996, 17:217-224.
34. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999, 29:1617-1625.
35. Lehner T, Bergmeier LA, Tao L, et al. Heat shock proteins generate β-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 2000, 30:594-603.
36. Babaahmady K, Bergmeier LA, Whittall T, et al. A comparative investigation of CC chemokines and SIV suppressor factors generated by CD8+ and CD4+ T cells and CD14+ monocytes. J Immunol Meth 2002, 264:1-10.
37. + T cells. Science 1995, 270:1811-1815.
38. Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996, 2:767-775.
39. Aubertin A-M, Wang Y, Le Grand R, et al. Generation of CD8-suppressor factor and β-chemokines by targeted iliac lymph node immunization in monkeys challenged with SHIV by the rectal route. AIDS Res Hum Retroviruses 2000, 16:381-392.
40. Wang Y, Tao L, Mitchell E, et al. Generation of CD8 suppressor factor and β chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques. Proc Natl Acad Sci USA 1998, 95:5223-5228.
41. Wang Y, Tao L, Mitchell E, et al. Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat Med 1999, 5:1004-1009.
42. Aramori I, Zhang J, Ferguson SSG, et al. Molecular mechanism of desensitization of the chemokine receptor CCR: receptor signalling and internalization are dissociable from its role as an HIV co-receptor. EMBO J 1997, 16:4606.
43. Lehner T, Wang Y, Cranage M, et al. Upregulation of β-chemokines and downmodulation of CCR5 Co-receptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology 2000, 99:569-577.
44. Abel K, Alegria-Hartman MJ, Zanotto K, et al. Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques. Cytokine 2001, 16:191-204.
45. Patterson BK, Landay A, Andersson J, et al. Repertoire of chemokine receptor expression in the female genital tract. Am J Pathol 1998, 153:481-490.
46. Spear GT, Sha BE, Saadoos MN, et al. Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women. J Acquin Immune Defic Syndr & Hum Retrovir 1998, 18:454-459.
47. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: toles in viral entry, tropism and disease. Annu Rev Immunol 1999, 17:657-700.
48. Amara A, Gall SL, Schwartz O, et al. HIV coreceptor down-regulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997, 186:139-146.
49. Agace WW, Amara A, Roberts AI, et al. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000, 10:325-328.
50. Anton PA, Elliott J, Poles MA, et al. Enhanced level of functional HIV-1 co-receptors on human mucosal T cell demonstrated using intestinal biopsy tissue. AIDS 2000, 14:1761-1765.
51. Clerici M, Shearer GM. A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993, 14:107-111.
52. + cell response against human immunodeficiency virus: Implications for long-term survival. Proc Natl Acad Sci USA 1995, 92:11135-11139.
53. Sinigaglia F, D'Ambrosia D, Panina-Bordignon P, Rogge L. Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function. Immunol Rev 1999, 170:65-72.
54. Chougnet C, Wynn TA, Clerici M, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Inf Dis 1996, 174:46-53.
55. Chehimi J, Start SE, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994, 179:1361-1366.
56. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemoklne receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998, 187:875-883.
57. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s). J Exp Med 1998, 187:129-134.
58. Zingoni A, Soto H, Dedrick JA, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not in Th1 cells. J Immunol 1998, 161:547-551.
59. Kim JJ, Nottingham LK, Sin JI, et al. CD8 positive T cells influence antigen-specific immune response through the expression of chemokines. J Clin Invest 1998, 102:1112-1124.
60. Zou W, Borvak J, Marches F, et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by β-chemokines rather than IL-12. J Immunol 2000, 165:4388-4396.
61. Mazzoli S, Trabattoni D, Lo CS, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Med 1997, 3:1250-1257.
62. Kaul R, Plimmer FA, Kimani J, et al. HIV-1 specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi. J Immunol 2000, 164:1602-1611.
63. Mazzoli S, Lopalco L, Salva A, et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999, 180:871-875.
64. DeVito C, Hinkula J, Kaul R, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000, 14:1917-1920.
65. Lehner T, Wang Y, Doyle C, et al. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques. Eur J Immunol 1999, 29:2427-2435.
66. Lehner T, Doyle C, Wang Y, et al. Immunogenicity of the extra-cellular domains of C-C chemokine receptor 5 and in vitro effects on simian immunodeficiency virus or HIV infectivity. J Immunol 2001, 166:7446-7455.
67. Ditzel HJ, Rosenkilde MM, Garred P, et al. The CCR5 receptor acts as an alloantigen in CCR5 Δ32 homozygous individuals: identification of chemokine and HIV-1 blocking human antibodies. Proc Natl Acad Sci USA 1998, 95:5241.
68. Lopalco L, Barassi C, Pastori C, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000, 164:3426.
69. Bouhlal H, Hocini H, Quillent-Gregoire C, et al. Antibodies to CC chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001, 166:7606-7611.
70. Zuber B, Hinkula J, Vodros D, et al. Induction of immune responses and break of tolerance by DNA against HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology 2000, 278:400-411.
71. Lohman BL, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol 1995, 155:5855-5860.
72. Klavinskis LS, Brookes R, Bergmeier LA, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in genito-rectal mucosa and draining lymph nodes. J Immunol 1996, 157:2521-2527.
73. Cox JC, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccine 1997, 15:248-256.
74. Moingeon P, Haensler J, Lindberg A. Towards the rational design of TH1 adjuvants. Vaccine 2001, 19:4363-4372.
75. nd Edition. Edited by Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR. Academic Press; 1999: 741-757.
76. Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988, 6:269-277.
77. Takahashi I, Marinaro M, Kiyono H, et al. Mechanism for mucosal immunogenicity and adjuvanticity of Escherichia coli labile enterotoxin. J Infect Dis 1996, 173:627-635.
78. nd Edition. Edited by Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR. Academic Press; 1999:759-778.
79. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Ann Rev Immunol 2000, 18:927-974.
80. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nature 2001, 1:209-219.
81. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector and memory immune responses. Ann Rev Immunol 2000, 18:593-620.
82. Wang Y, Kelly CG, Karttunen JT, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity 2001, 15:971-983.
83. Wang Y, Kelly CG, Singh M, et al. The effect of truncation of the peptide binding fragment of HSP70 on stimulation of CC chemokines and cytokines. J Immunol 2002, 169:2422-2429.
84. Lu X, Kiyono H, Lu D, et al. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protected rhesus macaques from vaginal challenge with SIVmac251. AIDS 1998, 12:1-10.
85. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997, 65:1387-1394.
86. Lundholm P, Asakura Y, Hinkula J, et al. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 1999, 17:2036-2042.
87. Lundholm P, Leandersson A-C, Christensson B, et al. DNA mucosal HIV vaccine in humans. Virus Res 2002, 82:141-145.
88. + T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
89. + T lymphocytes by attenuated simian immunodeficiency virus. J Virol 2000, 74:8762-8766.
90. Zaitseva M, Blauvelt A, Lee S, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nature Med 1997, 3:1369-1375.
91. Patterson BK, Landay A, Andersson J, et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 1998, 153:481-90.
92. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial trancytosis of HIV-1. J Immunol 2001, 166:6257-6258.
93. Robinson HL. New hope for an AIDS vaccine. Nature 2002, 2:239-250.
94. Mooij P, Heeny JL. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 2001, 20:304-321.
95. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
96. Crotty S, Miller SJ, Lohman BL, et al. Protection against simian immunodeficiency virus vaginal chellenge by using sabin poliovirus vectors. J Virol 2001, 75:7435-7452.
97. Finerty S, Stokes CR, Gruffydd-Jones TJ, et al. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 2001, 20:49-58.
98. Belyakov IM, Hel Z, Kelsall B, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Med 2001, 7:1320-1326.
99. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatis virus recombinants. Cell 2001, 106:539-549.
100. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey bu viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335.
101. Kantele A, Hakkinen M, Moldoveanu Z, et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: Evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun 1998, 66:5630-5635.
102. Devico AL, Fours TR, Shata MT, et al. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 2002, 20:1968-1974.
103. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med 2000, 6:207-210.
104. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med 2000, 6:200-206.